Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer to Use Sigma-Aldrich's ddRNAi Gene Silencing Tech

NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has granted Pfizer non-exclusive rights to its DNA-directed RNAi technology.
 
The agreement will allow Pfizer’s to use Sigma’s ddRNAi at any of its worldwide operations, Sigma said.
 
Sigma said it has exclusively licensed ddRNAi applications from Australian company Benitec and Australia’s Commonwealth Scientific and Industrial Research Organization.  
 
Financial terms of the agreement were not released.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.